NuCana PLC NCNA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
4.00quote price arrow up+0.02 (+0.50%)
Volume
7,856
52 week range
3.40 - 23.75
Loading...
  • Open4.04
  • Day High4.04
  • Day Low3.85
  • Prev Close3.98
  • 52 Week High23.75
  • 52 Week High Date06/26/23
  • 52 Week Low3.40
  • 52 Week Low Date04/19/24

Key Stats

  • Market Cap338,319.987
  • Shares Out84,580.00
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.00
  • YTD % Change-46.38

KEY STATS

  • Open4.04
  • Day High4.04
  • Day Low3.85
  • Prev Close3.98
  • 52 Week High23.75
  • 52 Week High Date06/26/23
  • 52 Week Low3.40
  • 52 Week Low Date04/19/24
  • Market Cap338,319.987
  • Shares Out84,580.00
  • 10 Day Average Volume0.03M
  • Dividend-
  • Dividend Yield-
  • Beta1.00
  • YTD % Change-46.38

RATIOS/PROFITABILITY

  • EPS (TTM)-20.46
  • P/E (TTM)-0.20
  • Fwd P/E (NTM)-0.00
  • EBITDA (TTM)-38.264M
  • ROE (TTM)-103.51%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)2.66%

EVENTS

  • Earnings Date05/15/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On NuCana PLC

 

Profile

MORE
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid...
Andrew Kay
Non-Executive Independent Chairman of the Board
Hugh Griffith
Chief Executive Officer, Co-Founder, Executive Director
Donald Munoz
Chief Financial Officer
Address
Lochside House, 3 Lochside Way
Edinburgh
EH12 9DT
United Kingdom

Top Peers

SYMBOLLASTCHG%CHG
ATHE
Alterity Therapeutics Ltd
2.14-0.06-2.73%
COEP
Coeptis Therapeutics Holdings Inc
0.3696+0.0298+8.7699%
MNPR
Monopar Therapeutics Inc
0.66+0.01+1.5385%
KPRX
Kiora Pharmaceuticals Inc
0.5426-0.0024-0.4404%
IKT
Inhibikase Therapeutics Inc
1.34-0.01-0.74%